MedDay’s Phase 3 Trial - impact on Optic Neuritis failed

[ElliotB]

I just saw this even though it is from a few months ago - hope it is not a duplication on TIMS.

MedDay’s MD-1003 PHASE III Optic Neuritis Trial Results For MS


A clinical trial of MedDay’s promising medication MD-1003 in a study of the drugs impact on Optic Neuritis failed to meet its endpoint in outperforming placebo towards improving vision for people who have multiple sclerosis.

Here is a link to the article (from May 10, 2017 ):

http://www.msunites.com/meddays-md-1003 ... ts-for-ms/



On a positive note, they are reporting positive results for patients with Progressive Multiple Sclerosis (although only 12.6% of patients taking MD1003 (biotin) had an improvement in their EDSS score.)

[Marc70]

Dude,

Where do you get your stuff from? This is like 1 1/2 years old....

http://www.medday-pharma.com/news-and-e ... is-at-aan/